| Identification | Back Directory | [Name]
4-Piperidinone, 1-[[1-[(2-fluorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methyl]-3,5-bis[(4-methylphenyl)methylene]-, (3E,5E)- | [CAS]
1983924-20-4 | [Synonyms]
MDK4204
MDK-4204
MDK 4204
Anticancer AgentI
Anticancer Agent-I
Anticancer Agent I
4-Piperidinone, 1-[[1-[(2-fluorophenyl)methyl]-1H-1,2,3-triazol-4-yl]methyl]-3,5-bis[(4-methylphenyl)methylene]-, (3E,5E)- | [Molecular Formula]
C31H29FN4O | [MOL File]
1983924-20-4.mol | [Molecular Weight]
492.59 |
| Hazard Information | Back Directory | [Uses]
Anticancer agent 255 is a monocarbonylated curcumin-1,2,3-oxazole conjugate with significant anticancer activity. The IC50 values of Anticancer agent 255 in prostate cancer cells PC-3 and DU-145 are 8.8μM and 9.5μM respectively. The IC50 values of Anticancer agent 255 against breast cancer cells MCF-7, MDA-MB-231 and 4T1 are 6μM, 10μM and 6.4μM, showing good anti-cancer activity Effect. Anticancer agent 255 can induce mitochondria-mediated apoptosis in cancer cells and prevent cell cycle progression. Anticancer agent 255 down-regulated the cell proliferation marker PCNA and inhibited the activation of cell survival proteins. Anticancer agent 255 up-regulated the pro-apoptotic protein Bax and down-regulated the anti-apoptotic protein Bcl-2[1]. | [References]
[1] Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines |
|
|